# US 2026/0218268 A1 · Compositions and methods for detecting gastrointestinal pathogens

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0218268 A1
- Document ID: US20260218268A1
- Status: Published application
- Kind: A1
- Application number: 19/146,189
- Filed: 2023-12-15
- Published: 2026-07-30
- Earliest claimed: 2022-12-19
- Assignees: Gen-Probe Incorporated
- Applicants: Gen-Probe Incorporated
- Inventors: Nesreen H. BARAKAT; Sree D. PANUGANTI; Tamara J. JOHNSON
- Web page: https://patentgrep.com/patent/US20260218268A1

## CPC

- C12Q 1/04: Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor {(C12Q1/6897 takes precedence)}
- C12Q 1/6813: Hybridisation assays
- C12Q 1/6844: Nucleic acid amplification reactions
- C12Q 1/689: for bacteria
- C12Q 2600/16: Primer sets for multiplex assays
- C12R 2001/19: Escherichia coli
- C12R 2001/63: Vibrio
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12R: INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS

## Abstract

Disclosed are nucleic acid oligomers, including amplification oligomers and detection probes, for detection of Yersinia enterocolitica, Vibrio spp., Shiga Toxin Expressing E. coli (STEC) O157, and Plesiomonas shigelloides target nucleic acid. Also disclosed are methods of specific nucleic acid amplification and detection using the disclosed oligomers, as well as corresponding formulations, reaction mixtures, and kits. Methods of synthesizing the nucleic acid oligomers are also disclosed.

## Claims

### Claim 1

(canceled)

### Claim 2

A composition or kit for determining the presence or absence of at least one enteric pathogen in a sample, wherein the at least one enteric pathogen is selected from the group consisting of Yersinia enterocolitica, Vibrio spp., Shiga Toxin Expressing E. coli (STEC) O157, and Plesiomonas shigelloides, said composition or kit comprising a set of oligonucleotides comprising at least one of (a)-(d):
(a) a Yersinia-specific amplification oligomer set capable of amplifying a target region of a Yersinia enterocolitica target nucleic acid, wherein the Yersinia-specific amplification oligomer set comprises first and second Yersinia-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO:26 and SEQ ID NO:46, including from 0 to 16 nucleotide analogs, (ii) SEQ ID NO:97 and SEQ ID NO:4, including from 0 to 16 nucleotide analogs, (iii) SEQ ID NO: 102 and SEQ ID NO:24, including from 0 to 16 nucleotide analogs, (iv) SEQ ID NO:6 and SEQ ID NO:24, including from 0 to 16 nucleotide analogs, (v) SEQ ID NO: 13 and SEQ ID NO:22, including from 0 to 16 nucleotide analogs, (vi) SEQ ID NO:77 and SEQ ID NO:22, including from 0 to 16 nucleotide analogs, (vii) SEQ ID NO:77 and SEQ ID NO:41, including from 0 to 16 nucleotide analogs, (viii) SEQ ID NO:28 and SEQ ID NO:30, including from 0 to 16 nucleotide analogs, (ix) SEQ ID NO:60 and SEQ ID NO:45, including from 0 to 16 nucleotide analogs, (x) SEQ ID NO:65 and SEQ ID NO:54, including from 0 to 16 nucleotide analogs, or (xi) SEQ ID NO: 10 and SEQ ID NO:4, including from 0 to 16 nucleotide analogs;
(b) a Vibrio-specific amplification oligomer set capable of amplifying a target region of a Vibrio spp. target nucleic acid, wherein the Vibrio spp. is one or more of V. parahaemolyticus, V. vulnificus, and V. cholerae, and wherein the Vibrio-specific amplification oligomer set comprises
(b-1) first and second V. parahaemolyticus-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO:51 and SEQ ID NO:76, including from 0 to 16 nucleotide analogs, (ii) SEQ ID NO:58 and SEQ ID NO:21, including from 0 to 16 nucleotide analogs, (iii) SEQ ID NO:58 and SEQ ID NO: 86, including from 0 to 16 nucleotide analogs, (iv) SEQ ID NO:53 and SEQ ID NO: 75, including from 0 to 16 nucleotide analogs, (v) SEQ ID NO:58 and SEQ ID NO:20, including from 0 to 16 nucleotide analogs, (vi) SEQ ID NO:52 and SEQ ID NO:75, including from 0 to 16 nucleotide analogs, (vii) SEQ ID NO:51 and SEQ ID NO:75, including from 0 to 16 nucleotide analogs, (viii) SEQ ID NO:52 and SEQ ID NO:76, including from 0 to 16 nucleotide analogs, or (ix) SEQ ID NO:53 and SEQ ID NO:76, including from 0 to 16 nucleotide analogs; and/or
(b-2) first and second V. vulnificus-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO:66 and SEQ ID NO:62, including from 0 to 16 nucleotide analogs, (ii) SEQ ID NO:58 and SEQ ID NO:21, including from 0 to 16 nucleotide analogs, (iii) SEQ ID NO:42 and SEQ ID NO:37, including from 0 to 16 nucleotide analogs, (iv) SEQ ID NO:55 and SEQ ID NO:37, including from 0 to 16 nucleotide analogs, (v) SEQ ID NO:43 and SEQ ID NO:78, including from 0 to 16 nucleotide analogs, (vi) SEQ ID NO:58 and SEQ ID NO:20, including from 0 to 16 nucleotide analogs, (vii) SEQ ID NO:42 and SEQ ID NO:84, including from 0 to 16 nucleotide analogs, (viii) SEQ ID NO:42 and SEQ ID NO:47, including from 0 to 16 nucleotide analogs, (ix) SEQ ID NO:55 and SEQ ID NO:84, including from 0 to 16 nucleotide analogs, (x) SEQ ID NO:55 and SEQ ID NO:47, including from 0 to 16 nucleotide analogs, or (xi) SEQ ID NO:55 and SEQ ID NO:5, including from 0 to 16 nucleotide analogs; and/or
(b-3) first and second V. cholerae-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO:56 and SEQ ID NO: 11, including from 0 to 16 nucleotide analogs, (ii) SEQ ID NO:32 and SEQ ID NO:3, including from 0 to 16 nucleotide analogs, (iii) SEQ ID NO:57 and SEQ ID NO:64, including from 0 to 16 nucleotide analogs, (iv) SEQ ID NO:94 and SEQ ID NO: 19, including from 0 to 16 nucleotide analogs, (v) SEQ ID NO:32 and SEQ ID NO: 105, including from 0 to 16 nucleotide analogs, (vi) SEQ ID NO:92 and SEQ ID NO: 3, including from 0 to 16 nucleotide analogs; (vii) SEQ ID NO:92 and SEQ ID NO: 105, including from 0 to 16 nucleotide analogs, (viii) SEQ ID NO:85 and SEQ ID NO:3, including from 0 to 16 nucleotide analogs, or (ix) SEQ ID NO:85 and SEQ ID NO: 105, including from 0 to 16 nucleotide analogs;
(c) a STEC-specific amplification oligomer set capable of amplifying a target region of a STEC O157 target nucleic acid, wherein the STEC-specific amplification oligomer set comprises first and second STEC-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO: 70 and SEQ ID NO: 16, including from 0 to 16 nucleotide analogs, (ii) SEQ ID NO:93 and SEQ ID NO:101, including from 0 to 16 nucleotide analogs, (iii) SEQ ID NO:71 and SEQ ID NO: 44, including from 0 to 16 nucleotide analogs, (iv) SEQ ID NO: 90 and SEQ ID NO: 100, including from 0 to 16 nucleotide analogs, (v) SEQ ID NO:71 and SEQ ID NO: 16, including from 0 to 16 nucleotide analogs, (vi) SEQ ID NO:70 and SEQ ID NO:44, including from 0 to 16 nucleotide analogs, (vii) SEQ ID NO:70 and SEQ ID NO: 107, including from 0 to 16 nucleotide analogs, (viii) SEQ ID NO:70 and SEQ ID NO:87, including from 0 to 16 nucleotide analogs, (ix) SEQ ID NO:71 and SEQ ID NO: 107, including from 0 to 16 nucleotide analogs, or (x) SEQ ID NO:71 and SEQ ID NO: 87, including from 0 to 16 nucleotide analogs; and
(d) a Plesiomonas-specific amplification oligomer set capable of amplifying a target region of a Plesiomonas shigelloides target nucleic acid, wherein the Plesiomonas-specific amplification oligomer set comprises first and second Plesiomonas-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO:2 and SEQ ID NO:49, including from 0 to 16 nucleotide analogs, (ii) SEQ ID NO:95 and SEQ ID NO: 1, including from 0 to 16 nucleotide analogs, (iii) SEQ ID NO:79 and SEQ ID NO:81, including from 0 to 16 nucleotide analogs, (iv) SEQ ID NO: 17 and SEQ ID NO: 1, including from 0 to 16 nucleotide analogs, (v) SEQ ID NO:95 and SEQ ID NO: 106, including from 0 to 16 nucleotide analogs, (vi) SEQ ID NO: 17 and SEQ ID NO: 106, including from 0 to 16 nucleotide analogs, (vii) SEQ ID NO:79 and SEQ ID NO:68, including from 0 to 16 nucleotide analogs, (viii) SEQ ID NO: 17 and SEQ ID NO:98, including from 0 to 16 nucleotide analogs, or (ix) SEQ ID NO:95 and SEQ ID NO:98, including from 0 to 16 nucleotide analogs.

### Claim 3 (depends on 2)

The composition or kit of claim 2, wherein the set of oligonucleotides comprises the Yersinia-specific amplification oligomer set.

### Claim 4

(canceled)

### Claim 5 (depends on 3)

The composition or kit of claim 3, wherein the set of oligonucleotides further comprises a Yersinia-specific detection probe comprising a target-hybridizing sequence substantially corresponding to the nucleotide sequence of
SEQ ID NO:40 if the Yersinia-specific amplification oligomer set comprises first and second Yersinia-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in SEQ ID NO:26 and SEQ ID NO:46, including from 0 to 16 nucleotide analogs;
SEQ ID NO:50 if the Yersinia-specific amplification oligomer set comprises first and second Yersinia-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO:97 and SEQ ID NO:4, including from 0 to 16 nucleotide analogs or (ii) SEQ ID NO: 10 and SEQ ID NO: 4, including from 0 to 16 nucleotide analogs;
SEQ ID NO:63 or SEQ ID NO:83 if the Yersinia-specific amplification oligomer set comprises first and second Yersinia-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO: 102 and SEQ ID NO:24, including from 0 to 16 nucleotide analogs or (ii) SEQ ID NO:6 and SEQ ID NO:24, including from 0 to 16 nucleotide analogs;
SEQ ID NO:29 if the Yersinia-specific amplification oligomer set comprises first and second Yersinia-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO: 13 and SEQ ID NO:22, including from 0 to 16 nucleotide analogs or (ii) SEQ ID NO:77 and SEQ ID NO:22, including from 0 to 16 nucleotide analogs;
SEQ ID NO:34 if the Yersinia-specific amplification oligomer set comprises first and second Yersinia-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in SEQ ID NO:77 and SEQ ID NO:41, including from 0 to 16 nucleotide analogs;
SEQ ID NO:27 if the Yersinia-specific amplification oligomer set comprises first and second Yersinia-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in SEQ ID NO:28 and SEQ ID NO:30, including from 0 to 16 nucleotide analogs;
SEQ ID NO:25 if the Yersinia-specific amplification oligomer set comprises first and second Yersinia-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in SEQ ID NO:60 and SEQ ID NO:45, including from 0 to 16 nucleotide analogs; or
SEQ ID NO: 18 if the Yersinia-specific amplification oligomer set comprises first and second Yersinia-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in SEQ ID NO:65 and SEQ ID NO:54, including from 0 to 16 nucleotide analogs.

### Claim 6

(canceled)

### Claim 7

(canceled)

### Claim 8 (depends on 2)

The composition or kit of claim 2, wherein the set of oligonucleotides comprises the first and second V. parahaemolyticus-specific amplification oligomers.

### Claim 9

(canceled)

### Claim 10 (depends on 8)

The composition or kit of claim 8, wherein the set of oligonucleotides further comprises a V. parahaemolyticus-specific detection probe comprising a target-hybridizing sequence substantially corresponding to the nucleotide sequence of
SEQ ID NO:33, SEQ ID NO:89, SEQ ID NO:91, or SEQ ID NO: 121 if the V. parahaemolyticus-specific amplification oligomer set comprises first and second V. parahaemolyticus-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO:51 and SEQ ID NO:76, including from 0 to 16 nucleotide analogs, (ii) SEQ ID NO:53 and SEQ ID NO:75, including from 0 to 16 nucleotide analogs, (iii) SEQ ID NO:52 and SEQ ID NO:75, including from 0 to 16 nucleotide analogs, (iv) SEQ ID NO:51 and SEQ ID NO:75, including from 0 to 16 nucleotide analogs, (v) SEQ ID NO:52 and SEQ ID NO:76, including from 0 to 16 nucleotide analogs, or (vi) SEQ ID NO:53 and SEQ ID NO:76, including from 0 to 16 nucleotide analogs; or
SEQ ID NO: 15 if the V. parahaemolyticus-specific amplification oligomer set comprises first and second V. parahaemolyticus-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO:58 and SEQ ID NO:21, including from 0 to 16 nucleotide analogs, (ii) SEQ ID NO:58 and SEQ ID NO:86, including from 0 to 16 nucleotide analogs, or (iii) SEQ ID NO:58 and SEQ ID NO:20, including from 0 to 16 nucleotide analogs.

### Claim 11

(canceled)

### Claim 12 (depends on 2)

The composition or kit of claim 2, wherein the set of oligonucleotides comprises the first and second V. vulnificus-specific amplification oligomers.

### Claim 13

(canceled)

### Claim 14 (depends on 12)

The composition or kit of claim 12, wherein the set of oligonucleotides further comprises a V. vulnificus-specific detection probe comprising a target-hybridizing sequence substantially corresponding to the nucleotide sequence of
SEQ ID NO:9 if the V. vulnificus-specific amplification oligomer set comprises first and second V. vulnificus-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO:66 and SEQ ID NO:62, including from 0 to 16 nucleotide analogs, (ii) SEQ ID NO:42 and SEQ ID NO:37, including from 0 to 16 nucleotide analogs, (iii) SEQ ID NO:55 and SEQ ID NO:37, including from 0 to 16 nucleotide analogs, (iv) SEQ ID NO:42 and SEQ ID NO:84, including from 0 to 16 nucleotide analogs, (v) SEQ ID NO:42 and SEQ ID NO:47, including from 0 to 16 nucleotide analogs, (vi) SEQ ID NO:55 and SEQ ID NO:84, including from 0 to 16 nucleotide analogs, (vii) SEQ ID NO:55 and SEQ ID NO:47, including from 0 to 16 nucleotide analogs, or (viii) SEQ ID NO:55 and SEQ ID NO:5, including from 0 to 16 nucleotide analogs; or
SEQ ID NO:31 if the V. vulnificus-specific amplification oligomer set comprises first and second V vulnificus-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO:58 and SEQ ID NO:21, including from 0 to 16 nucleotide analogs, (ii) SEQ ID NO:58 and SEQ ID NO:20, including from 0 to 16 nucleotide analogs, (iii) or (ii) SEQ ID NO:43 and SEQ ID NO:78, including from 0 to 16 nucleotide analogs.

### Claim 15

(canceled)

### Claim 16 (depends on 2)

The composition or kit of any one of claims claim 2, wherein the set of oligonucleotides comprises the first and second V. cholerae-specific amplification oligomers.

### Claim 17

(canceled)

### Claim 18 (depends on 16)

The composition or kit of claim 16, wherein the set of oligonucleotides further comprises a V. cholerae-specific detection probe comprising a target-hybridizing sequence substantially corresponding to the nucleotide sequence of
SEQ ID NO: 12 if the V. cholerae-specific amplification oligomer set comprises first and second V. cholerae-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in SEQ ID NO:56 and SEQ ID NO: 11, including from 0 to 16 nucleotide analogs;
SEQ ID NO:35 or SEQ ID NO:88 if the V. cholerae-specific amplification oligomer set comprises first and second V. cholerae-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO:32 and SEQ ID NO:3, including from 0 to 16 nucleotide analogs, (ii) SEQ ID NO:57 and SEQ ID NO:64, including from 0 to 16 nucleotide analogs, (iii) SEQ ID NO:32 and SEQ ID NO: 105, including from 0 to 16 nucleotide analogs, (iv) SEQ ID NO:92 and SEQ ID NO: 3, including from 0 to 16 nucleotide analogs; (v) SEQ ID NO:92 and SEQ ID NO: 105, including from 0 to 16 nucleotide analogs, (vi) SEQ ID NO:85 and SEQ ID NO:3, including from 0 to 16 nucleotide analogs, or (vii) SEQ ID NO:85 and SEQ ID NO: 105, including from 0 to 16 nucleotide analogs; or
SEQ ID NO:67 or SEQ ID NO:82 if the V. cholerae-specific amplification oligomer set comprises first and second V. cholerae-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in SEQ ID NO:94 and SEQ ID NO: 19, including from 0 to 16 nucleotide analogs.

### Claim 19

(canceled)

### Claim 20 (depends on 2)

The composition or kit of claim 2, wherein the set of oligonucleotides comprises the STEC-specific amplification oligomer set.

### Claim 21

(canceled)

### Claim 22 (depends on 20)

The composition or kit of claim 20, wherein the set of oligonucleotides further comprises a STEC-specific detection probe comprising a target-hybridizing sequence substantially corresponding to the nucleotide sequence of
SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:7, or SEQ ID NO:59 if the STEC-specific amplification oligomer set comprises first and second STEC-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO:70 and SEQ ID NO:16, including from 0 to 16 nucleotide analogs, (ii) SEQ ID NO:71 and SEQ ID NO:44, including from 0 to 16 nucleotide analogs, (iii) SEQ ID NO:71 and SEQ ID NO: 16, including from 0 to 16 nucleotide analogs, (iv) SEQ ID NO: 70 and SEQ ID NO:44, including from 0 to 16 nucleotide analogs, (v) SEQ ID NO:70 and SEQ ID NO: 107, including from 0 to 16 nucleotide analogs, (vi) SEQ ID NO:70 and SEQ ID NO:87, including from 0 to 16 nucleotide analogs, (vii) SEQ ID NO:71 and SEQ ID NO: 107, including from 0 to 16 nucleotide analogs, or (viii) SEQ ID NO:71 and SEQ ID NO:87, including from 0 to 16 nucleotide analogs;
SEQ ID NO:96 or SEQ ID NO: 103 if the STEC-specific amplification oligomer set comprises first and second STEC-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in SEQ ID NO:90 and SEQ ID NO:100, including from 0 to 16 nucleotide analogs;
SEQ ID NO:99 or SEQ ID NO: 104 if the STEC-specific amplification oligomer set comprises first and second STEC-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in SEQ ID NO:93 and SEQ ID NO: 101, including from 0 to 16 nucleotide analogs.

### Claim 23

(canceled)

### Claim 24 (depends on 2)

The composition or kit of claim 2, wherein the set of oligonucleotides comprises the Plesiomonas-specific amplification oligomer set.

### Claim 25

(canceled)

### Claim 26 (depends on 1)

The composition or kit of claim 1, wherein the set of oligonucleotides further comprises a Plesiomonas-specific detection probe comprising a target-hybridizing sequence substantially corresponding to the nucleotide sequence of
SEQ ID NO:48 if the Plesiomonas-specific amplification oligomer set comprises first and second Plesiomonas-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO:2 and SEQ ID NO:49, including from 0 to 16 nucleotide analogs or (ii) SEQ ID NO: 17 and SEQ ID NO:98, including from 0 to 16 nucleotide analogs;
SEQ ID NO:80, SEQ ID NO:72, or SEQ ID NO:61 if the Plesiomonas-specific amplification oligomer set comprises first and second Plesiomonas-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in_(i) SEQ ID NO:95 and SEQ ID NO: 1, including from 0 to 16 nucleotide analogs, (ii) SEQ ID NO: 17 and SEQ ID NO: 1, including from 0 to 16 nucleotide analogs, (iii) SEQ ID NO:95 and SEQ ID NO: 106, including from 0 to 16 nucleotide analogs, (iv) SEQ ID NO: 17 and SEQ ID NO: 106, including from 0 to 16 nucleotide analogs, (v) SEQ ID NO: 17 and SEQ ID NO:98, including from 0 to 16 nucleotide analogs, or (vi) SEQ ID NO:95 and SEQ ID NO:98, including from 0 to 16 nucleotide analogs; or
SEQ ID NO:8 if the Plesiomonas-specific amplification oligomer set comprises first and second Plesiomonas-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO:79 and SEQ ID NO:81, including from 0 to 16 nucleotide analogs or (ii) SEQ ID NO:79 and SEQ ID NO:68, including from 0 to 16 nucleotide analogs.

### Claim at position 27

27-29. (canceled)

### Claim 30 (depends on 2)

The composition or kit of claim 2, wherein the set of oligonucleotides comprises the Yersinia-specific amplification oligomer set, the Vibrio-specific amplification oligomer set, the STEC-specific amplification oligomer set, and the Plesiomonas-specific amplification oligomer set.

### Claim 31 (depends on 5)

The composition or kit of any one of claim 5, wherein the detection probe comprises
(i) a detectable label, optionally wherein the detectable label is a fluorescent or chemiluminescent label, and/or
(ii) a blocking moiety at or near the 3′ terminus, optionally wherein the blocking moiety is an inverted nucleotide.

### Claim at position 30

32-37. (canceled)

### Claim 38 (depends on 2)

A reaction mixture for determining the presence or absence of at least one enteric pathogen in a sample, said reaction mixture comprising a set of oligonucleotides as specified in claim 2.

### Claim 39

(canceled)

### Claim 40

(canceled)

### Claim 41

A method for determining the presence or absence of at least one enteric pathogen in a sample, wherein the at least one enteric pathogen is selected from the group consisting of Yersinia enterocolitica, Vibrio spp., Shiga Toxin Expressing E. coli (STEC) O157, and Plesiomonas shigelloides, the method comprising:
(1) contacting a sample, said sample suspected of containing the at least one enteric pathogen, with an oligomer combination capable of amplifying a target region of Yersinia enterocolitica, Vibrio spp., STEC O157, and/or Plesiomonas shigelloides target nucleic acid, said oligomer combination comprising
(a) a Yersinia-specific amplification oligomer set capable of amplifying a target region of a Yersinia enterocolitica target nucleic acid, wherein the Yersinia-specific amplification oligomer set comprises first and second Yersinia-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO:26 and SEQ ID NO:46, including from 0 to 16 nucleotide analogs, (ii) SEQ ID NO:97 and SEQ ID NO: 4, including from 0 to 16 nucleotide analogs, (iii) SEQ ID NO: 102 and SEQ ID NO: 24, including from 0 to 16 nucleotide analogs, (iv) SEQ ID NO:6 and SEQ ID NO:24, including from 0 to 16 nucleotide analogs, (v) SEQ ID NO: 13 and SEQ ID NO:22, including from 0 to 16 nucleotide analogs, (vi) SEQ ID NO:77 and SEQ ID NO:22, including from 0 to 16 nucleotide analogs, (vii) SEQ ID NO:77 and SEQ ID NO:41, including from 0 to 16 nucleotide analogs, (viii) SEQ ID NO:28 and SEQ ID NO:30, including from 0 to 16 nucleotide analogs, (ix) SEQ ID NO:60 and SEQ ID NO:45, including from 0 to 16 nucleotide analogs, (x) SEQ ID NO:65 and SEQ ID NO:54, including from 0 to 16 nucleotide analogs, or (xi) SEQ ID NO: 10 and SEQ ID NO:4, including from 0 to 16 nucleotide analogs; and/or
(b) a Vibrio-specific amplification oligomer set capable of amplifying a target region of a Vibrio spp. target nucleic acid, wherein the Vibrio spp. is one or more of V. parahaemolyticus, V. vulnifcus, and V. cholerae, and wherein the Vibrio-specific amplification oligomer set comprises
(b-1) first and second V. parahaemolyticus-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO:51 and SEQ ID NO:76, including from 0 to 16 nucleotide analogs, (ii) SEQ ID NO:58 and SEQ ID NO:21, including from 0 to 16 nucleotide analogs, (iii) SEQ ID NO:58 and SEQ ID NO:86, including from 0 to 16 nucleotide analogs, (iv) SEQ ID NO:53 and SEQ ID NO:75, including from 0 to 16 nucleotide analogs, (v) SEQ ID NO:58 and SEQ ID NO:20, including from 0 to 16 nucleotide analogs, (vi) SEQ ID NO:52 and SEQ ID NO:75, including from 0 to 16 nucleotide analogs, (vii) SEQ ID NO:51 and SEQ ID NO:75, including from 0 to 16 nucleotide analogs, (viii) SEQ ID NO:52 and SEQ ID NO:76, including from 0 to 16 nucleotide analogs, or (ix) SEQ ID NO:53 and SEQ ID NO:76, including from 0 to 16 nucleotide analogs; and/or
(b-2) first and second V. vulnificus-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO:66 and SEQ ID NO:62, including from 0 to 16 nucleotide analogs, (ii) SEQ ID NO:58 and SEQ ID NO:21, including from 0 to 16 nucleotide analogs, (iii) SEQ ID NO:42 and SEQ ID NO:37, including from 0 to 16 nucleotide analogs, (iv) SEQ ID NO:55 and SEQ ID NO:37, including from 0 to 16 nucleotide analogs, (v) SEQ ID NO:43 and SEQ ID NO:78, including from 0 to 16 nucleotide analogs, (vi) SEQ ID NO:58 and SEQ ID NO:20, including from 0 to 16 nucleotide analogs, (vii) SEQ ID NO:42 and SEQ ID NO:84, including from 0 to 16 nucleotide analogs, (viii) SEQ ID NO:42 and SEQ ID NO:47, including from 0 to 16 nucleotide analogs, (ix) SEQ ID NO:55 and SEQ ID NO:84, including from 0 to 16 nucleotide analogs, (x) SEQ ID NO:55 and SEQ ID NO:47, including from 0 to 16 nucleotide analogs, or (xi) SEQ ID NO:55 and SEQ ID NO:5, including from 0 to 16 nucleotide analogs; and/or
(b-3) first and second V. cholerae-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO:56 and SEQ ID NO: 11, including from 0 to 16 nucleotide analogs, (ii) SEQ ID NO:32 and SEQ ID NO:3, including from 0 to 16 nucleotide analogs, (iii) SEQ ID NO:57 and SEQ ID NO:64, including from 0 to 16 nucleotide analogs, (iv) SEQ ID NO:94 and SEQ ID NO: 19, including from 0 to 16 nucleotide analogs, (v) SEQ ID NO:32 and SEQ ID NO: 105, including from 0 to 16 nucleotide analogs, (vi) SEQ ID NO:92 and SEQ ID NO:3, including from 0 to 16 nucleotide analogs; (vii) SEQ ID NO:92 and SEQ ID NO: 105, including from 0 to 16 nucleotide analogs, (viii) SEQ ID NO:85 and SEQ ID NO:3, including from 0 to 16 nucleotide analogs, or (ix) SEQ ID NO:85 and SEQ ID NO: 105, including from 0 to 16 nucleotide analogs; and/or
(c) a STEC-specific amplification oligomer set capable of amplifying a target region of a STEC O157 target nucleic acid, wherein the STEC-specific amplification oligomer set comprises first and second STEC-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO:70 and SEQ ID NO: 16, including from 0 to 16 nucleotide analogs, (ii) SEQ ID NO:93 and SEQ ID NO:101, including from 0 to 16 nucleotide analogs, (iii) SEQ ID NO:71 and SEQ ID NO:44, including from 0 to 16 nucleotide analogs, (iv) SEQ ID NO:90 and SEQ ID NO: 100, including from 0 to 16 nucleotide analogs, (v) SEQ ID NO:71 and SEQ ID NO: 16, including from 0 to 16 nucleotide analogs, (vi) SEQ ID NO:70 and SEQ ID NO:44, including from 0 to 16 nucleotide analogs, (vii) SEQ ID NO:70 and SEQ ID NO: 107, including from 0 to 16 nucleotide analogs, (viii) SEQ ID NO:70 and SEQ ID NO:87, including from 0 to 16 nucleotide analogs, (ix) SEQ ID NO:71 and SEQ ID NO: 107, including from 0 to 16 nucleotide analogs, or (x) SEQ ID NO:71 and SEQ ID NO:87, including from 0 to 16 nucleotide analogs; and/or
(d) a Plesiomonas-specific amplification oligomer set capable of amplifying a target region of a Plesiomonas shigelloides target nucleic acid, wherein the Plesiomonas-specific amplification oligomer set comprises first and second Plesiomonas-specific amplification oligomers respectively comprising target-hybridizing sequences as shown in (i) SEQ ID NO:2 and SEQ ID NO:49, including from 0 to 16 nucleotide analogs, (ii) SEQ ID NO:95 and SEQ ID NO: 1, including from 0 to 16 nucleotide analogs, (iii) SEQ ID NO:79 and SEQ ID NO:81, including from 0 to 16 nucleotide analogs, (iv) SEQ ID NO: 17 and SEQ ID NO: 1, including from 0 to 16 nucleotide analogs, (v) SEQ ID NO:95 and SEQ ID NO: 106, including from 0 to 16 nucleotide analogs, (vi) SEQ ID NO: 17 and SEQ ID NO: 106, including from 0 to 16 nucleotide analogs, (vii) SEQ ID NO:79 and SEQ ID NO:68, including from 0 to 16 nucleotide analogs, (viii) SEQ ID NO: 17 and SEQ ID NO:98, including from 0 to 16 nucleotide analogs, or (ix) SEQ ID NO:95 and SEQ ID NO:98, including from 0 to 16 nucleotide analogs;
(2) performing an in vitro nucleic acid amplification reaction, wherein any Yersinia enterocolitica, Vibrio spp., STEC O157, and/or Plesiomonas shigelloides target nucleic acid present in the sample is used as a template for generating one or more amplification products corresponding to the Yersinia enterocolitica, Vibrio spp., STEC O157, and/or Plesiomonas shigelloides target regions; and
(3) detecting the presence or absence of the one or more amplification products, thereby determining the presence or absence of the at least one enteric pathogen in the sample.

### Claim 42 (depends on 41)

The method of claim 41, wherein
if the sample is contacted with the Yersinia-specific amplification oligomer set and any Yersinia enterocolitica target nucleic acid present in the sample is used as a template for generating a Yersinia enterocolitica amplification product corresponding to the Yersinia enterocolitica target region, then the detecting step (3) comprises contacting the in vitro nucleic acid amplification reaction with a Yersinia-specific detection probe configured to specifically hybridize to the Yersinia enterocolitica amplification product; and/or;
if the sample is contacted with the Vibrio-specific amplification oligomer set comprising the first and second V. parahaemolyticus-specific amplification oligomers and any V. parahaemolyticus target nucleic acid present in the sample is used as a template for generating a V. parahaemolyticus amplification product corresponding to the V. parahaemolyticus target region, then the detecting step (3) comprises contacting the in vitro nucleic acid amplification reaction with a V. parahaemolyticus-specific detection probe configured to specifically hybridize to the V. parahaemolyticus amplification product; and/or
if the sample is contacted with the Vibrio-specific amplification oligomer set comprising the first and second V. vulnificus-specific amplification oligomers and any V. vulnificus target nucleic acid present in the sample is used as a template for generating a V. vulnificus amplification product corresponding to the V vulnificus target region, then the detecting step (3) comprises contacting the in vitro nucleic acid amplification reaction with a V. vulnificus-specific detection probe configured to specifically hybridize to the V. vulnificus amplification product; and/or
if the sample is contacted with the Vibrio-specific amplification oligomer set comprising the first and second V. cholerae-specific amplification oligomers and any V. cholerae target nucleic acid present in the sample is used as a template for generating a V. cholerae amplification product corresponding to the V. cholerae target region, then the detecting step (3) comprises contacting the in vitro nucleic acid amplification reaction with a V. cholerae-specific detection probe configured to specifically hybridize to the V. cholerae amplification product; and/or
if the sample is contacted with the STEC-specific amplification oligomer set and any STEC O157 target nucleic acid present in the sample is used as a template for generating a STEC O157 amplification product corresponding to the STEC O157 target region; then the detecting step (3) comprises contacting the in vitro nucleic acid amplification reaction with a STEC-specific detection probe configured to specifically hybridize to the STEC O157 amplification product; and/or
if the sample is contacted with the Plesiomonas-specific amplification oligomer set and any Plesiomonas shigelloides target nucleic acid present in the sample is used as a template for generating a Plesiomonas shigelloides amplification product corresponding to the Plesiomonas shigelloides target region, then the detecting step (3) comprises contacting the in vitro nucleic acid amplification reaction with a Plesiomonas-specific detection probe configured to specifically hybridize to the Plesiomonas shigelloides amplification product.

### Claim 43

(canceled)

### Claim 44

(canceled)

### Claim 45 (depends on 41)

The method of claim 41, wherein the method is a multiplex method for detecting the presence or absence of each of Yersinia enterocolitica, Vibrio spp., Shiga Toxin Expressing E. coli (STEC) O157, and Plesiomonas shigelloides.

### Claim 46

(canceled)

### Claim 47

A method for synthesizing a pair of oligonucleotides, comprising synthesizing a first oligonucleotide and synthesizing a second oligonucleotide,
wherein each of the synthesizing the first oligonucleotide and the synthesizing the second oligonucleotide comprises the steps of:
(a) obtaining a solid support comprising at least one nucleobase residue, wherein the at least one nucleobase residue is covalently bound at a 3′ position to the solid support;
(b) coupling a 5′ position of the nucleobase residue furthest from the solid support to a 3′ position of another nucleobase residue;
(c) repeating step (b) at least 16 additional times, thereby generating at least 18 contiguous nucleobase residues coupled to the solid support; and
(d) cleaving the at least 18 contiguous nucleobase residues generated in step (c), thereby obtaining the oligonucleotide, and
wherein the first oligonucleotide and the second oligonucleotide respectively comprise the nucleotide sequences of any one of
SEQ ID NO:26 and SEQ ID NO:46, including from 0 to 16 nucleotide analogs;
SEQ ID NO:97 and SEQ ID NO:4, including from 0 to 16 nucleotide analogs;
SEQ ID NO: 102 and SEQ ID NO:24, including from 0 to 16 nucleotide analogs;
SEQ ID NO:6 and SEQ ID NO:24, including from 0 to 16 nucleotide analogs;
SEQ ID NO: 13 and SEQ ID NO:22, including from 0 to 16 nucleotide analogs;
SEQ ID NO:77 and SEQ ID NO:22, including from 0 to 16 nucleotide analogs;
SEQ ID NO:77 and SEQ ID NO:41, including from 0 to 16 nucleotide analogs;
SEQ ID NO:28 and SEQ ID NO:30, including from 0 to 16 nucleotide analogs;
SEQ ID NO:60 and SEQ ID NO:45, including from 0 to 16 nucleotide analogs;
SEQ ID NO:65 and SEQ ID NO:54, including from 0 to 16 nucleotide analogs;
SEQ ID NO: 10 and SEQ ID NO:4, including from 0 to 16 nucleotide analogs;
SEQ ID NO:51 and SEQ ID NO:76, including from 0 to 16 nucleotide analogs;
SEQ ID NO:58 and SEQ ID NO:21, including from 0 to 16 nucleotide analogs;
SEQ ID NO:58 and SEQ ID NO:86, including from 0 to 16 nucleotide analogs;
SEQ ID NO:53 and SEQ ID NO:75, including from 0 to 16 nucleotide analogs;
SEQ ID NO:58 and SEQ ID NO:20, including from 0 to 16 nucleotide analogs;
SEQ ID NO:52 and SEQ ID NO:75, including from 0 to 16 nucleotide analogs;
SEQ ID NO:51 and SEQ ID NO:75, including from 0 to 16 nucleotide analogs;
SEQ ID NO:52 and SEQ ID NO:76, including from 0 to 16 nucleotide analogs;
SEQ ID NO:53 and SEQ ID NO:76, including from 0 to 16 nucleotide analogs;
SEQ ID NO:66 and SEQ ID NO:62, including from 0 to 16 nucleotide analogs;
SEQ ID NO:58 and SEQ ID NO:21, including from 0 to 16 nucleotide analogs;
SEQ ID NO:42 and SEQ ID NO:37, including from 0 to 16 nucleotide analogs;
SEQ ID NO:55 and SEQ ID NO:37, including from 0 to 16 nucleotide analogs;
SEQ ID NO:43 and SEQ ID NO:78, including from 0 to 16 nucleotide analogs;
SEQ ID NO:58 and SEQ ID NO:20, including from 0 to 16 nucleotide analogs;
SEQ ID NO:42 and SEQ ID NO:84, including from 0 to 16 nucleotide analogs;
SEQ ID NO:42 and SEQ ID NO:47, including from 0 to 16 nucleotide analogs;
SEQ ID NO:55 and SEQ ID NO:84, including from 0 to 16 nucleotide analogs;
SEQ ID NO:55 and SEQ ID NO:47, including from 0 to 16 nucleotide analogs;
SEQ ID NO:55 and SEQ ID NO:5, including from 0 to 16 nucleotide analogs;
SEQ ID NO:56 and SEQ ID NO: 11, including from 0 to 16 nucleotide analogs;
SEQ ID NO:32 and SEQ ID NO:3, including from 0 to 16 nucleotide analogs;
SEQ ID NO:57 and SEQ ID NO:64, including from 0 to 16 nucleotide analogs;
SEQ ID NO:94 and SEQ ID NO: 19, including from 0 to 16 nucleotide analogs;
SEQ ID NO:32 and SEQ ID NO: 105, including from 0 to 16 nucleotide analogs;
SEQ ID NO:92 and SEQ ID NO:3, including from 0 to 16 nucleotide analogs;
SEQ ID NO:92 and SEQ ID NO: 105, including from 0 to 16 nucleotide analogs;
SEQ ID NO:85 and SEQ ID NO:3, including from 0 to 16 nucleotide analogs;
SEQ ID NO:85 and SEQ ID NO: 105, including from 0 to 16 nucleotide analogs;
SEQ ID NO:70 and SEQ ID NO: 16, including from 0 to 16 nucleotide analogs;
SEQ ID NO:93 and SEQ ID NO:101, including from 0 to 16 nucleotide analogs;
SEQ ID NO:71 and SEQ ID NO:44, including from 0 to 16 nucleotide analogs;
SEQ ID NO:90 and SEQ ID NO: 100, including from 0 to 16 nucleotide analogs;
SEQ ID NO:71 and SEQ ID NO: 16, including from 0 to 16 nucleotide analogs;
SEQ ID NO:70 and SEQ ID NO:44, including from 0 to 16 nucleotide analogs;
SEQ ID NO:70 and SEQ ID NO: 107, including from 0 to 16 nucleotide analogs;
SEQ ID NO:70 and SEQ ID NO:87, including from 0 to 16 nucleotide analogs;
SEQ ID NO:71 and SEQ ID NO: 107, including from 0 to 16 nucleotide analogs;
SEQ ID NO:71 and SEQ ID NO:87, including from 0 to 16 nucleotide analogs;
SEQ ID NO:2 and SEQ ID NO:49, including from 0 to 16 nucleotide analogs;
SEQ ID NO:95 and SEQ ID NO: 1, including from 0 to 16 nucleotide analogs;
SEQ ID NO:79 and SEQ ID NO:81, including from 0 to 16 nucleotide analogs;
SEQ ID NO: 17 and SEQ ID NO: 1, including from 0 to 16 nucleotide analogs;
SEQ ID NO:95 and SEQ ID NO: 106, including from 0 to 16 nucleotide analogs;
SEQ ID NO: 17 and SEQ ID NO: 106, including from 0 to 16 nucleotide analogs;
SEQ ID NO:79 and SEQ ID NO:68, including from 0 to 16 nucleotide analogs;
SEQ ID NO: 17 and SEQ ID NO:98, including from 0 to 16 nucleotide analogs; or
SEQ ID NO:95 and SEQ ID NO:98, including from 0 to 16 nucleotide analogs.
